217 related articles for article (PubMed ID: 33947523)
1. Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.
Leitinger EJ; Wright RM; Nelson N; Anderson MA; Juneja S
Pathology; 2021 Dec; 53(7):926-929. PubMed ID: 33947523
[No Abstract] [Full Text] [Related]
2. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
[No Abstract] [Full Text] [Related]
4. Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
Roulin L; Haioun C; Lemonnier F
Ann Hematol; 2021 May; 100(5):1345-1347. PubMed ID: 33655374
[No Abstract] [Full Text] [Related]
5. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Eyre TA; Walter HS; Iyengar S; Follows G; Cross M; Fox CP; Hodson A; Coats J; Narat S; Morley N; Dyer MJS; Collins GP
Haematologica; 2019 Feb; 104(2):e68-e71. PubMed ID: 30190341
[No Abstract] [Full Text] [Related]
7. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Le Gouill S; Morschhauser F; Chiron D; Bouabdallah K; Cartron G; Casasnovas O; Bodet-Milin C; Ragot S; Bossard C; Nadal N; Herbaux C; Tessoulin B; Tchernonog E; Rossi C; McCulloch R; Gastinne T; Callanan MB; Rule S
Blood; 2021 Feb; 137(7):877-887. PubMed ID: 33181832
[TBL] [Abstract][Full Text] [Related]
9. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
10. Hyperleukocytosis increases risk of fatal hyperkalemia with new ibrutinib/venetoclax regimen for refractory mantle cell lymphoma.
Verma A; Mbughuni M; Mariash E; Mesa H
J Chemother; 2019; 31(7-8):428-431. PubMed ID: 31738653
[No Abstract] [Full Text] [Related]
11. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F; Larkin K; Gregory CT; Orwick S; Doong TJ; Lozanski A; Lozanski G; Misra S; Ngankeu A; Ozer HG; Sampath D; Thangavadivel S; Yilmaz SA; Rogers KA; Byrd JC; Woyach JA; Blachly JS
Blood; 2020 Jun; 135(24):2192-2195. PubMed ID: 32232486
[No Abstract] [Full Text] [Related]
12. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
13. Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection.
Hindilerden F; Yönal Hindilerden İ; Diz Küçükkaya R
Balkan Med J; 2021 Mar; 38(2):141-142. PubMed ID: 33045824
[No Abstract] [Full Text] [Related]
14. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.
Agarwal R; Chan YC; Tam CS; Hunter T; Vassiliadis D; Teh CE; Thijssen R; Yeh P; Wong SQ; Ftouni S; Lam EYN; Anderson MA; Pott C; Gilan O; Bell CC; Knezevic K; Blombery P; Rayeroux K; Zordan A; Li J; Huang DCS; Wall M; Seymour JF; Gray DHD; Roberts AW; Dawson MA; Dawson SJ
Nat Med; 2019 Jan; 25(1):119-129. PubMed ID: 30455436
[TBL] [Abstract][Full Text] [Related]
15. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
17. Update on the CAPTIVATE trial of ibrutinib plus venetoclax.
Siddiqi T
Clin Adv Hematol Oncol; 2023 Dec; 21(12):654-657. PubMed ID: 38039059
[No Abstract] [Full Text] [Related]
18. Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma.
Zhou X; Steinhardt MJ; Düll J; Krummenast F; Danhof S; Meckel K; Nickel K; Grathwohl D; Leicht HB; Rosenwald A; Einsele H; Rasche L; Kortüm M
Eur J Haematol; 2020 Apr; 104(4):352-355. PubMed ID: 31922303
[TBL] [Abstract][Full Text] [Related]
19. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
Portell CA; Wages NA; Kahl BS; Budde LE; Chen RW; Cohen JB; Varhegyi NE; Petroni GR; Williams ME
Blood Adv; 2022 Mar; 6(5):1490-1498. PubMed ID: 34700344
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
